Professor Olson studied chemistry and neuroscience at Stanford and the Broad Institute of MIT and Harvard. His academic lab at UC Davis studies compound-induced neural plasticity. They coined the term “psychoplastogen” to describe small molecules that produce psychedelic-like effects on neuronal structure, and they invented the first non-hallucinogenic psychoplastogens capable of producing sustained therapeutic effects in preclinical models after a single dose. Professor Olson’s expertise spans central nervous system medicinal chemistry, molecular/cellular neurobiology, and behavioral neuropharmacology. He has received numerous awards including the Jordi Folch-Pi Award from the American Society for Neurochemistry, the MINS Rising Star Award, and the Sigma Xi Young Investigator Award, among many others. He is the founding director of the UC Davis Institute for Psychedelics and Neurotherapeutics and is a co-founder and the Chief Innovation Officer of Delix Therapeutics. |